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market authorization was retrieved from the EMA or MHRA. NICE positive decisions 
were compared to the market authorizations. Any decision that included language 
that restricted the population eligible for reimbursement for a given therapy was 
categorized as “recommend with restrictions.” NICE positive decisions that were not 
more restrictive than the market authorization were categorized as “recommend.” 
Negative decisions were categorized as “do not recommend.” Restrictions were also 
quantified and categorized. Results: NICE issued “do not recommend” decisions 
in 32% of the reviews from 2007-2013. The overall rate at which NICE issued “do not 
recommend” decisions increased after 2010, but this did not pass traditional levels of 
statistical significance (p= .21). NICE issued positive decisions in 68% of reviews, but 
the decision was more restrictive than the market authorization in 52% of the posi-
tive decisions. NICE’s restrictiveness has decreased since 2007, with the exception 
of 2013 where 60% of NICE’s positive decisions were “recommend with restrictions.” 
For the “recommend with restrictions” reviews, there are 1.7 restrictions on average 
(range 1-4, s.d. 11) added to the market authorization. The most prevalent type of 
restrictions were for contraindicated or intolerance.” ConClusions: In 2007-2013, 
NICE issued “recommend with restrictions” decisions in 36% of reviews and issued 
both “recommend” and “do not recommend” decisions in 32% of reviews. NICE was 
more restrictive than the market authorization in 52% of the positive decisions, 
though NICE’s restrictiveness seems to be declining over time. An independent 
analysis of NICE decisions in 2007-2013 found a statistically significant different 
distribution of decisions than reported in the NICE website (p= .01).
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objeCtives: Multicriteria Decision Analysis (MCDA) is an analytical quantitative 
instrument focused on supporting the decision-making process between alternative 
products based on multiple criteria. Methods: In the pilot study on MCDA applica-
tion in HTA in the Czech Republic, the following criteria were chosen by the experts: 
efficacy/effectiveness, safety, budget impact, disease severity, cost effectiveness 
and unmet needs. The number of evaluators was 10. Each evaluator determined 
weights within the range from 1 to 10 (from the least to the most important). The 
resultant weights were displayed as an arithmetic mean of weights of the indi-
vidual evaluators and as a trimmed mean with the minimum and maximum values 
discarded. The weights were also calculated by discarding the last evaluator, i.e. 
there were 4 sets of weights examined, each time normalized by 100%. Results: 
Each evaluator rated 5 chosen medicines with weights 0, 1, 2, 3 within the chosen 
categories. Afterwards, the mean scores and trimmed means with the lowest and 
the highest values discarded were determined for each of the 5 medicinal products 
chosen. All 8 estimates (4 weights times 2 mean scores) lead to the identical clas-
sification of medicinal products which proves the robustness of the approach. The 
biggest divergences between the evaluators‘ assessment of the same medicinal 
product was observed in case of its safety, whereas the slightest were considered 
the budget impact and cost-effectiveness. On the other hand, the differences in 
the cost-effectiveness assessment of the 5 medicinal products considered were 
followed by the greatest discrepancies as regards the budget impact. The MCDA s 
was compared with the classifications of the medicinal products based on the ICER 
only which revealed significant differences (e.g., 2nd place according to the ICER 
vs. 5th according to the MCDA). ConClusions: The MCDA brings new information 
with respect to the each criterion‘s separate application.
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objeCtives: Social preferences are widely used in economic evaluation required by 
regulatory agencies. In the UK, NICE requires the use of EQ-5D and its associated set 
of TTO preference weights for computing QALYs. The weights in question date back 
nearly two decades. It is reasonable to question whether they continue to represent 
contemporary social preferences. Were a revised set of EQ-5D weights to be pro-
duced then would this necessitate the revision of all past appraisal decisions? This 
paper presents the 1stphase of work designed to address that question. Methods: 
The ICER is defined by the ratio of marginal cost (Δ C) /marginal benefit (Δ B). For a 
given Δ C the ICER falls as Δ B increases. For a given threshold (λ ) and for a fixed incre-
mental cost (Δ C), there is a minimum health benefit Δ Bmin (given by Δ C/λ ) which 
must be achieved to produce an ICER that comes below that threshold limit. TTO-
weighted scores were computed for all 243 health states defined by the 3-level ver-
sion of EQ-5D. A difference matrix was created in which D(i,j) contains the numeric 
difference between the ith and jth state. The number of differences below a given 
Δ Bmin was computed for each column (health state). Threshold values were varied 
(£20,000-£50,000). Cost differences were varied (£500-£10,000). Results: Less than 
10% of health state value differences failed to meet the minimum Δ Bmin of 0.0125 
(Δ C = £500; λ = £20,000) indicating susceptability to changes in health state value, 
however this proportion rose to 57% for higher incremental costs (e.g. Δ C = £3,000). 
81/243 health states account for 50% of the differences that exceed Δ Bminat all 
tested levels of Δ C and λ . Graphical representation of these Results can be used 
to assess the need for reappraisal. ConClusions: For higher cost interventions, 
relatively small differences in EQ-5D weights can generate ICERs with the propensity 
to reverse previous cost-effectiveness decisions.
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objeCtives: Since its establishment in December 2011, Brazil’s HTA body CONITEC 
(National Commission on the Incorporation of Technologies), has published more 
than 90 assessments. The objective of the present study was to perform an analysis 
on CONITEC’s positive and negative decisions, in order to understand the main deci-
sion drivers. Methods: All assessments published by CONITEC between December 
2001 and April 2014 were included in our analysis. The rationale for the decisions 
was analyzed for both positive and negative recommendations. Reasons for recom-
mending or rejecting a technology were summarized into categories. Results: In 
total, 101 publications were identified: 67 of those assessed drugs, 12 a procedure or 
intervention and 11 a medical device. The remaining 11 were clinical guidelines (not 
included in the analysis). Overall, 46 recommendations were positive and 44 nega-
tive. The main reasons for rejection were concerns about the economic evidence 
(23 reports) or lack to demonstrate significant additional clinical benefits (22). The 
main reasons for positive recommendations were demonstrated clinical efficacy 
benefit (21), low budget impact (19) and fulfillment of high unmet needs (15). In 
the majority of cases, the decision was based on multiple factors. ConClusions: 
Brazil has set the way for a more transparent process for technology assessment 
following a formal process including pharmacoeconomic guidelines. However, insuf-
ficient clinical benefits and methodological concerns about the economic evalua-
tion as major rejection drivers reveals that manufacturers are not yet addressing 
CONITEC’s requirements. Full transparency on the evaluation of outcomes is still 
missing, providing additional complexity for manufacturers towards a positive rec-
ommendation. Our results demonstrated a positive relation between acceptance 
and demonstrated clinical efficacy, as well as a low budget impact. CONITEC seems 
to follow a specific pathway in their decision that should be leveraged by manufac-
turers in order to increase their likelihood of receiving a positive recommendation.
PHP210
tHe risky business of Drug DeveloPMent: tHe final say of national 
Hta agencies on a PHarMaceutical’s benefit During tHe last 
stretcH of an exPensive, long-lasting anD arDuous DeveloPMent 
Journey – as illustrateD by tHe Decisions of gerMany’s geMeinsaMer 
bunDesausscHuss (g-ba)
Maetzel A.1, Staab T.R.2, Ruof J.2
1Berlikon LLC, Chapel Hill, NC, USA, 2Roche Pharma, Grenzach-Wyhlen, Germany
objeCtives: Since 2011 Germany follows a formal process of evaluating new phar-
maceuticals for their incremental benefit vs. an appropriate comparator to inform 
price negotiations with Insurers. This study summarizes the rationale underlying 
the German authorities’ (G-BA) final assessment of manufacturers’ submissions 
following successful approval by regulators. Methods: G-BA decisions (1/2011 to 
2/2014) were evaluated for their alignment (full, partial or none) between manu-
facturer’s development programs and expectations concerning: (1) target popula-
tion; (2) comparator; (3) clinical endpoints, including indirect comparisons. Also 
addressed was the role of safety and how the G-BA addressed the potential for 
bias. Results: Of 69 completed submissions, 3 were resubmissions and 7 lacked 
a dossier. 59 completed submissions were subjected to a detailed review. Ten (17%) 
were for orphan disease indications. Major disagreement existed for 37 (63%), of 
which 17 (46%) were considered fully inadequate, and 20 (54%) inadequate for sig-
nificant subgroups. Main reasons for inadequacy were: wrong comparator (27 of 37 
[73%], wrong endpoint 6 [16%] and use of historical controls (3 [11%]). For 34 (92%) 
the major disagreement also led to a lower benefit judgment. All 19 indirect treat-
ment comparisons were considered flawed. Safety was a differentiator for 24 of the 
59 submissions, either primary (2) or in addition to efficacy (22). G-BA disagreed 
with the manufacturer on safety for 12 (50%) of the 24 submissions. ConClusions: 
This analysis of the first 3 years of G-BA’s early benefit appraisal illustrates that a 
majority of the submissions fail to convince the German authorities despite having 
obtained licensing approval. A wrong comparator was the main reason for full or 
partial rejection. Indirect treatment comparisons were never accepted. Decisions 
taken early in the development program have important repercussions on reim-
bursement negotiations with authorities in Germany.
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objeCtives: Harmonisation of health technology assessment (HTA) processes 
between countries is a logical and efficient solution to complex data gathering 
exercises required of pharmaceutical manufacturers when preparing submissions. 
However, harmonisation is a slow process and potentially substantial differences 
between countries exist. Further, some types of data will inevitably need to be 
country-specific to meet local HTA requirements. Epidemiological data can be 
considered one such source of information. Methods: We reviewed HTA require-
ments in Australia, England and Wales, Japan and Scotland for epidemiology data 
requirements in their submission. Specific data types were identified and compared 
across the geographical regions. Results: Clear requirements were available for 
Australia (Pharmaceutical Benefits Advisory Committee [PBAC]), England and Wales 
(National Institute for Health and Care Excellence [NICE]), and Scotland (Scottish 
Medicines Consortium [SMC]). As of April 2014, there is an ongoing development 
